Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 20Unknown 8Recruiting 6Not yet recruiting 6Terminated 2Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Hemangioma, Capillary 2Premature Birth 1Hemangioma 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Population Groups × Clear all
NCT01147601 2017-07-05

Topical Timolol 0.5% Solution for Proliferating Infantile Hemangiomas

Oregon Health and Science University

Phase EARLY_PHASE1 Terminated
6 enrolled 7 charts

Hemangioma, Hemangioma, Capillary

NCT01434849 2016-11-15

TiPPIH

The University of Texas Health Science Center at San Antonio

Phase 1 Terminated
26 enrolled

Hemangioma, Capillary, Premature Birth

Data powered by HemOnc (CC BY 4.0) Colophon âš¡